| Literature DB >> 29991650 |
Guillaume Gaud1, Romain Roncagalli2, Karima Chaoui3, Isabelle Bernard1, Julien Familiades1, Céline Colacios1, Sahar Kassem1, Bernard Monsarrat3, Odile Burlet-Schiltz3, Anne Gonzalez de Peredo3, Bernard Malissen2,4, Abdelhadi Saoudi5.
Abstract
The activation of T cells requires the guanine nucleotide exchange factor VAV1. Using mice in which a tag for affinity purification was attached to endogenous VAV1 molecules, we analyzed by quantitative mass spectrometry the signaling complex that assembles around activated VAV1. Fifty VAV1-binding partners were identified, most of which had not been previously reported to participate in VAV1 signaling. Among these was CD226, a costimulatory molecule of immune cells. Engagement of CD226 induced the tyrosine phosphorylation of VAV1 and synergized with T cell receptor (TCR) signals to specifically enhance the production of interleukin-17 (IL-17) by primary human CD4+ T cells. Moreover, co-engagement of the TCR and a risk variant of CD226 that is associated with autoimmunity (rs763361) further enhanced VAV1 activation and IL-17 production. Thus, our study reveals that a VAV1-based, synergistic cross-talk exists between the TCR and CD226 during both physiological and pathological T cell responses and provides a rational basis for targeting CD226 for the management of autoimmune diseases.Entities:
Year: 2018 PMID: 29991650 DOI: 10.1126/scisignal.aar3083
Source DB: PubMed Journal: Sci Signal ISSN: 1945-0877 Impact factor: 8.192